Full Breakdown
Nationwide Recall of Prazosin Hydrochloride Capsules Due to Carcinogen Concerns
11/1/2025, 9:53:23 PM
Overview of the Recall
Teva Pharmaceuticals USA has initiated a voluntary recall of nearly 581,000 bottles of prazosin hydrochloride capsules, a medication primarily used to treat high blood pressure and sometimes prescribed off-label for post-traumatic stress disorder (PTSD) symptoms. The recall was prompted by tests revealing elevated levels of a potentially carcinogenic impurity, specifically N-nitroso prazosin impurity C, which exceeded the U.S. Food and Drug Administration's (FDA) acceptable safety limits. The recall was classified as a Class II risk level by the FDA on October 24, indicating that exposure may cause temporary or medically reversible adverse health consequences, though the probability of serious adverse health consequences is considered remote.
Details of the Affected Products
The recall encompasses three dosage strengths of prazosin hydrochloride capsules:
- 1 mg capsules: 181,659 bottles
- 2 mg capsules: 291,512 bottles
- 5 mg capsules: 107,673 bottles
These capsules were distributed nationwide and are available in bottle sizes ranging from 100 to 1,000 capsules, with expiration dates extending from October 2025 to February 2027.
Health Implications and Recommendations
Patients currently taking the recalled medication are advised not to abruptly discontinue use, as this could lead to dangerous spikes in blood pressure. Instead, they should consult their healthcare provider or pharmacist to discuss alternative treatment options and determine if their medication is affected by the recall. Teva Pharmaceuticals has communicated with customers via letters regarding the recall and has instructed pharmacies to remove the affected lots from circulation.
Official Statements
Teva Pharmaceuticals stated, “Prazosin is indicated for the treatment of hypertension, to lower blood pressure, and there are many alternative treatments available to patients.” The company emphasized its commitment to patient safety and product quality, noting that it had not received any relevant complaints related to the recalled product.
Criticism and Concerns
Despite the FDA's classification of the recall as Class II, concerns remain regarding the implications of long-term exposure to nitrosamine impurities, which are linked to an increased risk of cancer. The FDA has urged patients to remain vigilant and consult their healthcare providers before making any changes to their medication regimen.
Conflicting Reports & Gaps
While the recall affects over 580,000 bottles, some reports indicate that the total number of recalled bottles may approach 590,000. Additionally, the specific lot numbers and expiration dates for the affected products have been detailed in FDA enforcement reports, but not all sources provide comprehensive information on these specifics.
What's Next
The FDA continues to monitor the situation and has called for increased scrutiny in pharmaceutical manufacturing processes to prevent future occurrences of similar issues. Patients are encouraged to stay informed and consult their healthcare providers for guidance regarding their medications.
Verbatim Quotes
- “This recall has been initiated in coordination with the FDA and to date Teva has not received any relevant complaints related to this product,” — Teva Pharmaceuticals
- “stopping your medicine may be more harmful to your health than continuing to take the recalled medicine” — FDA Advisory
This recall serves as a reminder of the importance of rigorous testing and quality control in the pharmaceutical industry to ensure patient safety.
